{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menieres-disease/prescribing-information/promethazine-teoclate/","result":{"pageContext":{"chapter":{"id":"0c353f7c-323c-5e3b-9872-1e6533f5abad","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate","depth":2,"htmlHeader":"<!-- begin field 89a4928c-4a96-4ec2-9454-179f75a2ea61 --><h2>Promethazine teoclate</h2><!-- end field 89a4928c-4a96-4ec2-9454-179f75a2ea61 -->","summary":"","htmlStringContent":"<!-- begin item 144e9e2b-d252-48e3-9394-a1278d8b80b5 --><!-- end item 144e9e2b-d252-48e3-9394-a1278d8b80b5 -->","topic":{"id":"c2b20ab8-7e5a-5868-9804-8a9d6a2cb567","topicId":"193a65ca-1981-44e6-a5d3-781aa5010b2c","topicName":"Meniere's disease","slug":"menieres-disease","lastRevised":"Last revised in November 2017","chapters":[{"id":"16b06288-e565-5867-9311-37b626851eb0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"47494f3b-a0fd-53b2-8613-2cd38f1a11dd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"371c2958-24a9-5d9c-ae14-b7539d491674","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d13d990c-bded-5655-aa70-40268a150cbd","slug":"changes","fullItemName":"Changes"},{"id":"c184f0c8-2419-565f-ab73-a1a5591fc29d","slug":"update","fullItemName":"Update"}]},{"id":"9c1b726a-8066-5632-89ef-7764e1edd1d3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8ee08c5c-67dd-57f0-b666-7d874024d8ed","slug":"goals","fullItemName":"Goals"},{"id":"7fd84935-e76b-56af-b285-b58ed2a8ecc2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"981ad1f7-1003-50fc-8e49-411ea1ff34d4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4307ba4c-2b7b-54c0-9103-71e4a18f16ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"416a0198-b8a8-5272-8684-3aa5a380fc74","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2221f812-317a-569e-a4bc-0183f833d0f7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"272bf558-6edb-531a-a2d4-4b19639383ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"25e37eb8-40b6-5b11-b9d3-4fe5378e1524","slug":"definition","fullItemName":"Definition"},{"id":"65d7cb18-66af-5447-8401-2c8e24d64dd4","slug":"cause","fullItemName":"Cause"},{"id":"4f2a2237-790f-5b99-9650-34b58a75512e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ed8dbd0f-7c6b-53bf-a2b9-77006586ab7e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a4342e8b-12e6-56d8-a716-190cac3ce652","slug":"complications","fullItemName":"Complications"},{"id":"5b357eed-7df9-57ca-9c0d-0511ecf6f601","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"318e7c3d-c3c6-5a60-be9d-9179e643d3fb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0ae90882-dae2-56da-b987-8bca0eefb6b3","slug":"suspecting-menieres-disease","fullItemName":"Suspecting Meniere's disease"},{"id":"7fc93a60-260c-5030-a14e-d6375907f198","slug":"making-a-diagnosis","fullItemName":"Making a diagnosis"},{"id":"73c5b8af-f846-541f-a7d9-48e2c6b9679c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f2772f3-1ee5-5ca8-8c0c-bb2454b53670","fullItemName":"Management","slug":"management","subChapters":[{"id":"ed30823a-3e70-58a0-9411-f17351fb2c44","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0b1be20b-b94c-56a6-a221-cbea038b74ec","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2054a7c4-97a4-57e7-a3de-05ea67cfa502","slug":"betahistine","fullItemName":"Betahistine"},{"id":"2e656ebe-784a-562f-8aca-85a4aa0f56bb","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"73881eee-9a58-575f-9d06-545fa1f67335","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"584ce48e-7ea7-5ee0-874b-1c99ccbdb8fa","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"0c353f7c-323c-5e3b-9872-1e6533f5abad","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"5de25a19-1810-510b-ba6b-c9b9979fb4c6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f893c00d-a15b-572d-8042-6164f0ee4141","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"18f58ee1-0ff6-5c45-b4a3-5f2f22070e03","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"41de5190-f85f-57eb-81a1-fa4aad3af7b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9e4161b0-4719-5539-99e5-e094855a17d0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5a5f7056-1236-5638-904d-dce7e2b843af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2b63dcde-7589-5a5a-b219-7f2ff2e0b527","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a8e9bf2-d409-5815-8467-31e3a6379930","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0b1be20b-b94c-56a6-a221-cbea038b74ec","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"f2f31dfd-6157-5e7c-86ae-42b21121bea8","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 0f869d9e-edd6-4c34-b182-a81000f0ad7d --><h3>What dosage of promethazine teoclate should I prescribe?</h3><!-- end field 0f869d9e-edd6-4c34-b182-a81000f0ad7d -->","summary":"","htmlStringContent":"<!-- begin item e054f2e0-9c52-48d0-afe9-a81000f0ab29 --><!-- begin field d720716a-e31a-4ef9-86ba-a81000f0ad7d --><ul><li>Prescribe promethazine teoclate 25 mg orally at night. The dose may be increased to 100 mg daily.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">MHRA, 2017</a>] </p><!-- end field d720716a-e31a-4ef9-86ba-a81000f0ad7d --><!-- end item e054f2e0-9c52-48d0-afe9-a81000f0ab29 -->","subChapters":[]},{"id":"441e7db1-62c8-5c7b-ba1d-9bcdfe8daa0a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 985ded54-19b1-431b-82fb-a81000f0d15d --><h3>What are the contraindications and cautions when prescribing promethazine teoclate?</h3><!-- end field 985ded54-19b1-431b-82fb-a81000f0d15d -->","summary":"","htmlStringContent":"<!-- begin item 77eaf1e7-0c95-4d55-bac7-a81000f0cfb2 --><!-- begin field ff3900eb-f976-47f6-a101-a81000f0d15d --><ul><li><strong>Promethazine teoclate should not be used in people with:</strong><ul><li>Hypersensitivity to promethazine, its excipients, or other phenothiazines.</li><li>Central nervous system (CNS) depression of any cause.</li><li>Exposure to monoamine oxidase inhibitors within the previous 14 days.</li><li>Severe liver disease — increased risk of coma.</li></ul></li><li><strong>Promethazine teoclate should be used with caution in people with:</strong><ul><li>Hepatic or renal impairment.</li><li>Severe coronary artery disease.</li><li>Urinary retention or prostatic hypertrophy.</li><li>Angle-closure glaucoma.</li><li>Pyloroduodenal obstruction.</li><li>Epilepsy.</li><li>Asthma, bronchitis, or bronchiectasis — promethazine teoclate may thicken or dry lung secretions and impair expectoration.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">MHRA, 2017</a>] </p><!-- end field ff3900eb-f976-47f6-a101-a81000f0d15d --><!-- end item 77eaf1e7-0c95-4d55-bac7-a81000f0cfb2 -->","subChapters":[]},{"id":"fed873cc-4b74-5ae4-a917-865ccd2a42c5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 78af9f49-1650-49bf-b379-a81000f0eef4 --><h3>What are the adverse effects of promethazine teoclate?</h3><!-- end field 78af9f49-1650-49bf-b379-a81000f0eef4 -->","summary":"","htmlStringContent":"<!-- begin item 029d7dcf-621a-48b5-8d94-a81000f0ed53 --><!-- begin field 8462cac7-e652-4883-af92-a81000f0eef4 --><p><strong>Adverse effects of promethazine include:</strong></p><ul><li>Neurological — dizziness, confusion, restlessness, headaches, nightmares, sedation (affected people should not drive or operate heavy machinery), tremor, muscle spasms and tic-like movements of the head and face, extrapyramidal effects.</li><li>Antimuscarinic effects — blurred vision, dry mouth, and urinary retention.</li><li>Skin — rash, photosensitivity.</li><li>Gastrointestinal — anorexia, gastric irritation, jaundice (rare).</li><li>Cardiovascular — palpitations, hypotension, arrhythmias.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">MHRA, 2017</a>] </p><!-- end field 8462cac7-e652-4883-af92-a81000f0eef4 --><!-- end item 029d7dcf-621a-48b5-8d94-a81000f0ed53 -->","subChapters":[]},{"id":"5130c684-29b8-5346-9e07-82b7f2ab7651","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a9bb6c12-7163-4e50-9c63-a81000f11df5 --><h3>What drug interactions occur with promethazine?</h3><!-- end field a9bb6c12-7163-4e50-9c63-a81000f11df5 -->","summary":"","htmlStringContent":"<!-- begin item 78ee2f71-a53b-428d-9a0c-a81000f11c4f --><!-- begin field a2bb7c7b-62d6-41dd-af29-a81000f11df5 --><ul><li>Drug interactions with promethazine include:<ul><li>Opioid analgesics — sedative effects may be enhanced when promethazine is given with opioid analgesics.</li><li>Alcohol — sedative effects may be increased by the combination of promethazine and alcohol.</li><li>Antimuscarinic drugs, tricyclic antidepressants, sedatives, and hypnotics — concomitant use with promethazine enhances the antimuscarinic and/or sedative action of these drugs.</li></ul></li><li>Promethazine has the potential to interact with immunological pregnancy tests (may give false-positive or false-negative results). It may also give a false negative result with skin tests by inhibiting the cutaneous histamine response — discontinue 72 hours in advance.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">MHRA, 2017</a>] </p><!-- end field a2bb7c7b-62d6-41dd-af29-a81000f11df5 --><!-- end item 78ee2f71-a53b-428d-9a0c-a81000f11c4f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}